Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + temozolomide + Optune
- Development stage
- Unknown
- Lead developer
- NovoCure GmbH
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Topical
01
Overview
Pembrolizumab + temozolomide + Optune is a combination regimen currently in Phase 3 clinical development (EF-41/KEYNOTE D58) for the treatment of newly diagnosed glioblastoma. The regimen combines the immune checkpoint inhibitor pembrolizumab (Keytruda), which targets the PD-1 receptor on T-cells, with the standard-of-care chemotherapy temozolomide and NovoCure's Optune device. Optune delivers Tumor Treating Fields (TTFields), which are low-intensity, alternating electric fields tuned to 200 kHz to interfere with the division of glioblastoma cells by disrupting mitotic spindle assembly. This multi-modal approach aims to improve overall survival by simultaneously stimulating the immune system, inducing DNA damage, and physically inhibiting cell replication.
- Brand names
- KeytrudaOptune
- Other names
- TTFieldsTumor Treating Fields
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + temozolomide + Optune.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + temozolomide + Optune.